Allergy Therapeutics PLC PDMR dealing and Total Voting Rights (6930W)
December 13 2023 - 11:54AM
UK Regulatory
TIDMAGY
RNS Number : 6930W
Allergy Therapeutics PLC
13 December 2023
Allergy Therapeutics plc
("Allergy Therapeutics", or the "Company")
Exercise of Options, PDMR dealing and Total Voting Rights
13 December 2023 Allergy Therapeutics plc (AIM: AGY), the
integrated commercial biotechnology company specialising in allergy
vaccines, announces that, further to his intention outlined in the
mandatory offer document published on 19 October 2023, Manuel
Llobet, Chief Executive Officer of the Company, exercised options
over 1,676,200 ordinary shares ("Ordinary Shares") in the Company
on 16 November 2023, which were granted at nominal value pursuant
to the Company's 2013 Long Term Incentive Plan. The Ordinary Shares
were issued and subsequently admitted to trading on 1 December 2023
pursuant to the Company's block admission facility.
Following the option exercise, Manuel Llobet holds 5,001,200
Ordinary Shares in the Company, representing approximately 0.10% of
the issued share capital of the Company.
Pursuant to the Company's block admission facility, the Company
also issued 888,967 Ordinary Shares in satisfaction of the exercise
of share options by certain other current and former employees.
These Ordinary Shares were also admitted to trading on 1 December
2023. The share options were exercised prior to or on 16 November
2023 as a result of the recent equity financing that constituted a
change of control for the purposes of the Company's Long Term Share
Incentive Plan. Any options not exercised by 16 November 2023 have
lapsed.
The new Ordinary Shares rank pari passu with the Company's
existing shares.
Total Voting Rights
In accordance with DTR 5.6.1 of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, as at 13
December 2023, the Company has 4,766,439,938 Ordinary Shares in
issue. There are no shares held in treasury. The total number of
voting rights in the Company is therefore 4,766,439,938.
The above figure of 4,766,439,938 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
- ENDS -
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong , Chief Financial Officer
+44 (0)1903 845 820
Panmure Gordon
Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0) 20 7886 2500
ICR Consilium
Mary-Jane Elliott / David Daley / Davide Salvi
+44 20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company, headquartered in the UK, focussed on the
treatment and diagnosis of allergic disorders, including aluminium
free immunotherapy vaccines that have the potential to cure
disease. The Group sells proprietary and third-party products from
its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad
pipeline of products in clinical development includes vaccines for
grass, tree, house dust mite and peanut. For more information,
please see www.allergytherapeutics.com .
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Manuel Llobet
----------------------------- -----------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------
a) Position/status Person Discharging Managerial Responsibilities
(PDMR) - Ch ief E xecutive Officer
----------------------------- -----------------------------------------------
b) Initial notification Initial Notification
/Amendment
----------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Allergy Therapeutics plc
----------------------------- -----------------------------------------------
b) LEI 213800PQ7AHK7KGVOE23
----------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the financial Options over ordinary shares of GBP0.001
instrument, type of each
instrument
Identification code ISIN: GB00B02LCQ05
b) Nature of the transaction Exercise of options
----------------------------- -----------------------------------------------
c) Price(s) and volume(s) Volume: 1,676,200
Exercise price: GBP0.001
----------------------------- -----------------------------------------------
d) Aggregated information N/A
----------------------------- -----------------------------------------------
e) Date of the transaction 16 November 2023
----------------------------- -----------------------------------------------
f) Place of the transaction Outside of a trading venue
----------------------------- -----------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBLBDDUDBDGXX
(END) Dow Jones Newswires
December 13, 2023 11:54 ET (16:54 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024